Validation study of a comprehensive geriatric assessment for the management of elderly patients with advanced pancreatic cancer

Validation study of a comprehensive geriatric assessment for the management of elderly patients with advanced pancreatic cancer - Validation study of a comprehensive geriatric assessment for the management of elderly patients with advanced pancreatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030070

Enrollment

Registered

2018-01-01

Start date

2018-01-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

Selection of chemotherapy regimen using comprehensive geriatric assessment 1. Fit -&gt

Gemcitabine+Nab-paclitaxel 2. Vulnerabel -&gt

Gemcitabine 3. Frail -&gt

Best supportive care

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chemotherapy is under consideration for advanced or recurrence pancreatic cancer

Exclusion criteria

Exclusion criteria: Patients who are going to receive resection or chemoradiation.

Design outcomes

Primary

Measure	Time frame
Time to treatment failure, TTF	—

Secondary

Measure	Time frame
1) overall survival 2) progression free survival 3) adverse events	—

Countries

Japan

Contacts

Public ContactOsamu Maeda

Nagoya University Hospital Department of Clinical Oncology and Chemotherapy

maeda-o@med.nagoya-u.ac.jp052-741-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026